吡格列酮对实验性动脉粥样硬化大鼠血脂水平的影响及临床意义

目的观察吡格列酮对高脂饮食诱导动脉粥样硬化模型大鼠血脂水平的影响,并探索其临床意义。方法设清洁型SD大鼠26只,随机分为对照组(n=9)、高脂饮食组(n=17),高脂饮食组喂养12周后再随机分为模型组(n=8)和吡格列酮组(n=9),分别给予蒸馏水、蒸馏水(1.5ml/100g)和吡格列酮10mg/(kg·d)灌胃,1次/d,同时继续高脂饮食,干预4周后,检测各组血脂水平并观察主动脉病理形态学改变。结果高脂饮食喂养12周后,与对照组相比,模型组和吡格列酮组三酰甘油(TG)、总胆固醇(TC)显著升高(P<0.01)。给药干预4周后,吡格列酮组干预后TG、TC、低密度脂蛋白胆固醇(LDL-C)较干预前明显降低(P<0.01),与模型组比较,吡格列酮组TG、TC水平明显降低(P<0.01)。且可减轻高脂饮食诱导的主动脉内膜增厚和平滑肌细胞增殖。结论吡格列酮可改善高脂血症大鼠血脂水平,延缓主动脉粥样硬化病理改变,提示吡格列酮的抗动脉粥样硬化作用可能部分归于血脂改善效应。

Influence of pioglitazone on lipid levels in experimental model rats of atherosclerosis and its clinical significance

Objective To investigate the change of lipid levels in high-fat diets induced atherosclerotic rats treated with pioglitazone, and to explore its clinical significance. Methods Twenty-six male SD rats were randomly divided into control group (n=9) and high-fat diets group (n=17). High-fat diets group received high-fat diets for 12 weeks, and then were randomly devided into model group (n=8) and pioglitazone-treated group (n=9). The control group, model group and pioglitazone-treated group received intragastric administration with distilled water, distilled water (1.5 ml/100 g) and pioglitazone 10 mg/(kg·d) respectively. Meanwhile, all animals continued to receive high-fat diets. After 4 weeks, the serum lipid level of all rats was measured, and the aortic pathological changes were observed. Results Compared with control group, the serum levels of TG, TC in model group and pioglitazone-treated group were significantly higher after 12 weeks’ high-fat diets(P<0.01).After intervention with pioglitazone for 4 weeks, the serum levels of TG, TC and LDL-C were decreased (P<0.01). Moreover, the serum levels of TG, TC in pioglitazone-treated group was markedly lower than those in model group(P<0.01). Aortic thickening and smooth muscle cell proliferation were induced in high-fat diets group. Conclusions Pioglitazone can improve lipid levels in hyperlipidemia rats, delay the pathological changes in aortic atherosclerosis, suggesting that the effect of pioglitazone on anti-atherosclerosis may be partly attributed to the improvement of blood lipid.